{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T22:58:39Z","timestamp":1768258719829,"version":"3.49.0"},"reference-count":19,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","gastrojournal.org","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastroenterology"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1053\/j.gastro.2016.06.032","type":"journal-article","created":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T20:29:10Z","timestamp":1467404950000},"page":"234-237","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Gemcitabine Activates Natural Killer Cells to Attenuate Pancreatic Cancer Recurrence"],"prefix":"10.1053","volume":"151","author":[{"given":"David W.","family":"Dawson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin E.","family":"Fernandez-Zapico","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/j.gastro.2016.06.032_bib1","series-title":"Cancer facts & figures\u00a02016","first-page":"1","year":"2016"},{"key":"10.1053\/j.gastro.2016.06.032_bib2","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1158\/0008-5472.CAN-14-0155","article-title":"Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States","volume":"74","author":"Rahib","year":"2014","journal-title":"Cancer Res"},{"key":"10.1053\/j.gastro.2016.06.032_bib3","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1053\/j.gastro.2013.01.078","article-title":"Therapeutic advances in pancreatic cancer","volume":"144","author":"Paulson","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2016.06.032_bib4","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/nrclinonc.2015.53","article-title":"Pancreatic cancer: from state-of-the-art treatments to promising novel therapies","volume":"12","author":"Garrido-Laguna","year":"2015","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1053\/j.gastro.2016.06.032_bib5","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1053\/j.gastro.2012.03.002","article-title":"What we have learned about pancreatic cancer from mouse models","volume":"142","author":"Perez-Mancera","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2016.06.032_bib6","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1053\/j.gastro.2016.05.004","article-title":"Administration of gemcitabine after pancreatic tumor resection in mice induces an antitumor immune response mediated by natural killer cells","volume":"151","author":"G\u00fcrlevik","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2016.06.032_bib7","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1002\/(SICI)1098-2744(199802)21:2<81::AID-MC1>3.0.CO;2-R","article-title":"Amplification and overexpression of the AKT2 oncogene in a subset of human pancreatic ductal adenocarcinomas","volume":"21","author":"Ruggeri","year":"1998","journal-title":"Mol Carcinog"},{"key":"10.1053\/j.gastro.2016.06.032_bib8","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1101\/gad.1415606","article-title":"Genetics and biology of pancreatic ductal adenocarcinoma","volume":"20","author":"Hezel","year":"2006","journal-title":"Genes Dev"},{"key":"10.1053\/j.gastro.2016.06.032_bib9","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1001\/jama.2013.279201","article-title":"Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial","volume":"310","author":"Oettle","year":"2013","journal-title":"JAMA"},{"key":"10.1053\/j.gastro.2016.06.032_bib10","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.cellimm.2015.02.003","article-title":"Using chemo-drugs or irradiation to break immune tolerance and facilitate immunotherapy in solid cancer","volume":"294","author":"Zheng","year":"2015","journal-title":"Cell Immunol"},{"key":"10.1053\/j.gastro.2016.06.032_bib11","doi-asserted-by":"crossref","first-page":"516","DOI":"10.3389\/fimmu.2015.00516","article-title":"Exploiting the Immunomodulatory Properties of Chemotherapeutic Drugs to Improve the Success of Cancer Immunotherapy","volume":"6","author":"Kersten","year":"2015","journal-title":"Front Immunol"},{"key":"10.1053\/j.gastro.2016.06.032_bib12","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/ijc.27990","article-title":"Low-dose gemcitabine depletes regulatory T cells and improves survival in the orthotopic Panc02 model of pancreatic cancer","volume":"133","author":"Shevchenko","year":"2013","journal-title":"Int J Cancer"},{"key":"10.1053\/j.gastro.2016.06.032_bib13","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1200\/JCO.2014.57.4244","article-title":"Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer","volume":"33","author":"Le","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1053\/j.gastro.2016.06.032_bib14","doi-asserted-by":"crossref","first-page":"6713","DOI":"10.1158\/1078-0432.CCR-05-0883","article-title":"Gemcitabine selectively eliminates splenic Gr-1+\/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity","volume":"11","author":"Suzuki","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.gastro.2016.06.032_bib15","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1007\/s12094-013-1079-0","article-title":"Changes in the immune cell population and cell proliferation in peripheral blood after gemcitabine-based chemotherapy for pancreatic cancer","volume":"16","author":"Homma","year":"2014","journal-title":"Clin Transl Oncol"},{"key":"10.1053\/j.gastro.2016.06.032_bib16","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1093\/jjco\/hyp112","article-title":"Regular dose of gemcitabine induces an increase in CD14+ monocytes and CD11c+ dendritic cells in patients with advanced pancreatic cancer","volume":"39","author":"Soeda","year":"2009","journal-title":"Jpn J Clin Oncol"},{"key":"10.1053\/j.gastro.2016.06.032_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2015.10.001","article-title":"Bench to bedside: NK cells and control of metastasis","author":"Krasnova","year":"2015","journal-title":"Clin Immunol"},{"key":"10.1053\/j.gastro.2016.06.032_bib18","doi-asserted-by":"crossref","first-page":"e0139809","DOI":"10.1371\/journal.pone.0139809","article-title":"Contrasting effects of\u00a0the cytotoxic anticancer drug gemcitabine and the EGFR tyrosine kinase inhibitor gefitinib on NK cell-mediated\u00a0cytotoxicity via regulation of NKG2D ligand in non-small-cell lung cancer cells","volume":"10","author":"Okita","year":"2015","journal-title":"PLoS One"},{"key":"10.1053\/j.gastro.2016.06.032_bib19","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1097\/MPA.0000000000000288","article-title":"Effect of surgery on pancreatic tumor-dependent lymphocyte asset: modulation of natural killer cell frequency and cytotoxic function","volume":"44","author":"Iannone","year":"2015","journal-title":"Pancreas"}],"container-title":["Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0016508516347047?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0016508516347047?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,2]],"date-time":"2022-07-02T15:08:40Z","timestamp":1656774520000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0016508516347047"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8]]},"references-count":19,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,8]]}},"alternative-id":["S0016508516347047"],"URL":"https:\/\/doi.org\/10.1053\/j.gastro.2016.06.032","relation":{},"ISSN":["0016-5085"],"issn-type":[{"value":"0016-5085","type":"print"}],"subject":[],"published":{"date-parts":[[2016,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Gemcitabine Activates Natural Killer Cells to Attenuate Pancreatic Cancer Recurrence","name":"articletitle","label":"Article Title"},{"value":"Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.gastro.2016.06.032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1053\/j.gastro.2016.05.004","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 by the AGA Institute","name":"copyright","label":"Copyright"}]}}